Sernova Shares Jump With AstraZeneca Collaboration
By Robb M. Stewart
Sernova's shares rallied Wednesday after the biotechnology company entered a preclinical research collaboration with AstraZeneca to evaluate the use of its Cell Pouch System in combination with AstraZeneca's novel therapeutic cells.
In morning trading, the shares were 18% higher at C$1.07, widening the year-to-date advance to 35%.
Sernova said AstraZeneca is exploring the use of the Cell Pouch System as a potential platform for integration with its development of the next wave of cell therapies for various indications. Under the terms of the collaboration, AstraZeneca will lead and completely fund the development of the cell technologies and preclinical activities in conjunction with Sernova. The discovery work is being funded and conducted at AstraZeneca, Sernova said.
Preclinical research outcomes will determine the feasibility of potential therapeutic applications and subsequent product development activities between the two companies, said Sernova, which has developed a cell therapy approach for the potential treatment of insulin-dependent diabetes, hypothyroidism and hemophilia A.
Write to Robb M. Stewart at robb.stewart@wsj.com
(END) Dow Jones Newswires
May 03, 2023 11:16 ET (15:16 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
5 Stocks to Buy That We Still Like After They’ve Run Up
-
Markets Brief: Stocks Are Starting to Look Cheap Again
-
Will Earnings From These 10 AI Stocks Live Up to the Hype?
-
What’s Happening In the Markets This Week
-
What the Next Bitcoin Halving Means for ETF Investors
-
Going Into Earnings, Is Microsoft a Buy, a Sell, or Fairly Valued?
-
10 Best Blue-Chip Stocks to Buy for the Long Term
-
After Earnings, Is Netflix Stock a Buy, a Sell, or Fairly Valued?
-
ServiceNow Earnings: Strong Quarter With In-Line Guidance and Increasingly Attractive Valuation
-
Ford Earnings: Pro Continues to Impress While EV Costs Are Contained
-
Boeing Earnings: Paying for Mistakes Made Long Ago, Taking Back the Factory Floor
-
Meta Earnings: Stock Now Fairly Valued After Latest Selloff
-
March PCE Inflation Index Forecasts Show Mixed Readings On Price Pressures
-
After Earnings, Is Charles Schwab Stock a Buy, a Sell, or Fairly Valued?